H. Jürgens

7.7k total citations
138 papers, 5.4k citations indexed

About

H. Jürgens is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, H. Jürgens has authored 138 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 26 papers in Pathology and Forensic Medicine. Recurrent topics in H. Jürgens's work include Sarcoma Diagnosis and Treatment (54 papers), Neuroblastoma Research and Treatments (21 papers) and Lymphoma Diagnosis and Treatment (18 papers). H. Jürgens is often cited by papers focused on Sarcoma Diagnosis and Treatment (54 papers), Neuroblastoma Research and Treatments (21 papers) and Lymphoma Diagnosis and Treatment (18 papers). H. Jürgens collaborates with scholars based in Germany, Austria and United States. H. Jürgens's co-authors include Michael Paulussen, Winfried Winkelmann, Jürgen Dunst, Jörn Treuner, Stefan Bielack, J. Ritter, A. Zoubek, K. Winkler, S. Ahrens and D. Harms and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

H. Jürgens

134 papers receiving 5.2k citations

Peers

Countries citing papers authored by H. Jürgens

Since Specialization

Citations

This map shows the geographic impact of H. Jürgens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Jürgens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Jürgens more than expected).

Fields of papers citing papers by H. Jürgens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Jürgens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Jürgens. The network helps show where H. Jürgens may publish in the future.

Co-authorship network of co-authors of H. Jürgens

This figure shows the co-authorship network connecting the top 25 collaborators of H. Jürgens. A scholar is included among the top collaborators of H. Jürgens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Jürgens. H. Jürgens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Local Control and Survival in Pelvic Ewing Sarcoma (EwS) in the Euro-Ewing99 Trial 2016 ·Pediatric Blood & Cancer ·Uta Dirksen, H. Jürgens, Andreas Ranft, Daniel Baumhoer, Henk van den Berg, Siebren Dijkstra, Hans Gelderblom, Georg Gosheger, Jendrik Hardes, (unknown), Ruth Ladenstein, Andreas Leithner, Michael Paulussen, Arne Streitbuerger, Beate Timmermann, (unknown), Wolfgang Hartmann, Reinhard Windhager, Dimosthenis Andreou	3
2	Osteosarcoma: The COSS Experience 2009 ·Cancer treatment and research ·Stefan Bielack, H. Jürgens, Gernot Jundt, Matthias Kevric, Thomas Kühne, Peter Reichardt, A. Zoubek, Mathias Werner, Winfried Winkelmann, R. Kotz	147
3	Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients 2008 ·Journal of Clinical Oncology ·Michael Paulussen, Alan Craft, Ian Lewis, Allan Hackshaw, (unknown), Jürgen Dunst, Andreas Schuck, Winfried Winkelmann, Gabriele Köhler, Christopher Poremba, A. Zoubek, Ruth Ladenstein, Henk van den Berg, Andrea Hunold, A.M. Cassoni, D. Spooner, R. J. Grimer, Jeremy Whelan, Anne McTiernan, H. Jürgens	171
4	Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors 2006 ·Pediatric Blood & Cancer ·Andrea Hunold, (unknown), Michael Paulussen, Andreas Ranft, (unknown), H. Jürgens	112
5	Concomitant Ewing sarcoma and acute lymphoblastic leukemia in a 5-year-old girl 2005 ·Pediatric Blood & Cancer ·Katja Masjosthusmann, Stefan Bielack, Gabriele Köhler, (unknown), Manfred Schiborr, Jochen Bruch, Dirk Reinhardt, (unknown), Michael Paulussen, H. Jürgens	7
6	Prospective longitudinal evaluation of doxorubicin‐induced cardiomyopathy in sarcoma patients: A report of the late effects surveillance system (LESS) 2005 ·Pediatric Blood & Cancer ·Marios Paulides, (unknown), Wolfgang Stöhr, Stefan Bielack, H. Jürgens, J. Treuner, Jörn D. Beck, Thorsten Langer	50
7	Evaluation of Chemotherapy Response in Primary Bone Tumors with F-18 FDG Positron Emission Tomography Compared with Histologically Assessed Tumor Necrosis 2000 ·Clinical Nuclear Medicine ·Christiane Franzius, J. Sciuk, C. Brinkschmidt, H. Jürgens, Otmar Schober	108
8	Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone 1997 ·Journal of Cancer Research and Clinical Oncology ·Yoshinao Oda, Barbara Dockhorn‐Dworniczak, H. Jürgens, Albert Roessner	16
9	Significance of surgical margin on the prognosis of patients with Ewing's sarcoma: A report from the Cooperative Ewing's Sarcoma Study 1996 ·Cancer ·Toshifumi Ozaki, Axel Hillmann, Christiane Hoffmann, Christian Rübe, S. Blasius, Jürgen Dunst, H. Jürgens, Winfried Winkelmann	104
10	Therapy of childhood acute myelogenous leukemias 1996 ·Annals of Hematology ·Josef Vormoor, Joachim Boos, Karsten Stahnke, H. Jürgens, J. Ritter, Ursula Creutzig	15
11	An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia 1995 ·Cancer ·Lawrence J. Ettinger, Joanne Kurtzberg, (unknown), H. Jürgens, Steven Halpern	76
12	Significance of the SCID Mouse Models for the Study of Normal and Leukemic Human Hemopoiesis and Gene Therapy 1995 ·Oncology Research and Treatment ·Josef Vormoor, J. Ritter, H. Jürgens, John E. Dick	2
13	Ewing's sarcoma of the ribs. A report from the Cooperative Ewing's Sarcoma Study 1995 ·European Journal of Cancer ·Toshifumi Ozaki, Norbert Lindner, Caroline Hoffmann, A. Hillmann, Robert Rödl, S. Blasius, Thomas M. Link, Winfried Winkelmann, H. Jürgens	21
14	Specificity and function of monoclonal antibodies directed against Ewing sarcoma cells 1994 ·Cancer Immunology Immunotherapy ·(unknown), (unknown), F Borchard, H. Jürgens, U. Göbel, E. M. Schneider	6
15	Total body hyperthermia in combination with etoposide and melphalan in a child with acute myelomonocytic leukemia 1994 ·Medical and Pediatric Oncology ·Rüdiger Wessalowski, (unknown), H. Jürgens, (unknown), U. Göbel	6
16	Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report. 1993 ·PubMed ·Joachim Boos, (unknown), H. Gerding, H. Jürgens	5
17	Synovial sarcoma of childhood and adolescence. Report of the german CWS-81 study 1993 ·Cancer ·Ruth Ladenstein, Helmut Gadner, Jörn Treuner, Eva Koscielniak, F d'Oleire, (unknown), D. Niethammer, H. Jürgens, J. Ritter, Dietmar Schmidt	75
18	Ondansetron as Prophylaxis for Chemotherapy and Radiotherapy-Induced Emesis in Children 1992 ·Oncology ·H. Jürgens, B. McQuade	39
19	Langerhans Cell Histiocytosis Masquerading as Lichen Aureus 1991 ·Pediatric Dermatology ·Mosaad Megahed, Hans‐Christian Schuppe, Erhard Hölzle, H. Jürgens, Gerd Plewig	5
20	Behandlungsergebnisse beim primär metastasierten Ewing-Sarkom Eine retrospektive Analyse von 48 Patienten 1988 ·Klinische Pädiatrie ·R. Wessalowski, H. Jürgens, H. Bodenstein, W. Brandeis, (unknown), W. Havers, (unknown), R. Kotz, Jørgen Tobias Kühl, M. Salzer‐Kuntschik, (unknown), Voûte Pa, P. Weinel, K. Winkler, U. Göbel	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact